Experimental and Clinical Regenerative Capability of Human Bone Marrow Cells After Myocardial Infarction
2004; Lippincott Williams & Wilkins; Volume: 95; Issue: 7 Linguagem: Inglês
10.1161/01.res.0000144798.54040.ed
ISSN1524-4571
AutoresFrancisco Fernández‐Avilés, José Alberto San Román, Javier García‐Frade, María Eugenia Fernández‐Santos, María Jesús Peñarrubia, Luis de la Fuente, Manuel Gómez‐Bueno, Alberto María Torre Cantalapiedra, Jesús Fernández, Oliver Gutiérrez, Pedro L. Sánchez, Carolina Hernández, Ricardo Sanz, Javier García‐Sancho, Ana Sánchez,
Tópico(s)Electrospun Nanofibers in Biomedical Applications
ResumoBone marrow mononuclear cells (BMCs) from 20 patients with extensive reperfused myocardial infarction (MI) were used to assess their myocardial regenerative capability “in vitro” and their effect on postinfarction left ventricular (LV) remodeling. Human BMCs were labeled, seeded on top of cryoinjured mice heart slices, and cultured. BMCs showed tropism for and ability to graft into the damaged mouse cardiac tissue and, after 1 week, acquired a cardiomyocyte phenotype and expressed cardiac proteins, including connexin43. In the clinical trial, autologous BMCs (78±41×10 6 per patient) were intracoronarily transplanted 13.5±5.5 days after MI. There were no adverse effects on microvascular function or myocardial injury. No major cardiac events occurred up to 11±5 months. At 6 months, magnetic resonance showed a decrease in the end-systolic volume, improvement of regional and global LV function, and increased thickness of the infarcted wall, whereas coronary restenosis was only 15%. No changes were found in a nonrandomized contemporary control group. Thus, BMCs are capable of nesting into the damaged myocardium and acquire a cardiac cell phenotype in vitro as well as safely benefiting ventricular remodeling in vivo. Large-scale randomized trials are needed now to assess the clinical efficacy of this treatment.
Referência(s)